Aidoc vs RapidAI: Stroke and Acute AI Triage Software Compared

The short answer: Aidoc and RapidAI are both FDA-cleared acute triage platforms, but they are not really the same product. Aidoc sells breadth: one platform that flags many different urgent findings across CT, CTA and X-ray, and in January 2026 it cleared the first multi-condition body CT triage device, folding 14 indications into a single pass. RapidAI sells depth in stroke and vascular disease, where it has the strongest published comparative evidence any imaging AI vendor currently holds. If you are buying for a comprehensive stroke center, RapidAI is the sharper instrument. If you are buying for a busy emergency department that wants one contract covering pulmonary embolism, hemorrhage, aortic and spine findings alongside stroke, Aidoc's platform shape fits better. Neither publishes list pricing.

Updated August 2026. Both vendors clear new modules several times a year, so confirm the current indication list with each before you build a shortlist around this article.

Aidoc vs RapidAI at a glance

The table below is the comparison most procurement conversations actually need. Everything in it is either public regulatory record or a vendor-stated figure, labeled as such.

Sources: the FDA AI-Enabled Medical Device List, Q1 2026 snapshot; each vendor's own clearance announcements; the American Journal of Neuroradiology, May 2026. Vendor-stated figures are the vendors' own and we have not independently audited them. Compiled August 2026.

What each company is actually selling

The clearance counts hide the more useful distinction. Aidoc built a platform first and algorithms second. Its pitch to a health system is that one integration, one security review and one contract cover a growing list of urgent findings, and that adding the next pathology is a configuration change rather than a new procurement. The January 2026 body CT clearance is the clearest expression of that strategy: rather than clearing another single-finding detector, Aidoc cleared a single device that triages 14 indications from one scan, driven by its CARE foundation model. The company reported mean sensitivity of 97% and mean specificity of 98% across the 11 new indications in the submission data.

RapidAI went the other way. It picked the one imaging AI use case where software plausibly changes an outcome, built the deepest product in it, and has spent a decade accumulating clinical evidence there. Its November 2025 clearances are revealing: Rapid LMVO extends vessel coverage on CTA, Rapid MLS quantifies midline shift, Rapid DeltaFuse tracks change over time. Those are not triage flags. They are measurement tools for a neuro service line, which is a different product category from a worklist reorderer.

Both approaches are legitimate. They just fail differently. A broad platform can end up with modules nobody opens and an average performance profile across pathologies your site rarely sees. A deep specialist can leave you buying a second vendor eighteen months later for the pathologies it does not cover, which is a real cost we worked through in how many radiology AI vendors a practice needs.

Which is better, Aidoc or RapidAI?

Neither is better in the abstract, and the honest answer depends on one question: is your bottleneck stroke, or is it everything arriving in the emergency department at 2am? RapidAI holds the only peer-reviewed head-to-head result in this category and it is a strong one, but it covers large vessel occlusion detection only. Aidoc holds a broader cleared footprint and a platform that absorbs new pathologies without a new integration. Match the tool to the bottleneck you can actually measure.

Where RapidAI is genuinely stronger

The evidence base is the difference. The DUEL study, published in the American Journal of Neuroradiology in May 2026, ran RapidAI and Viz.ai simultaneously on 1,589 consecutive code strokes at one comprehensive stroke center. RapidAI detected 144 of 147 confirmed large vessel occlusions, 98%, against 73% for Viz.ai, and processed 99.9% of studies against 90%. That is not a comparison against Aidoc, so it does not settle this particular matchup. What it establishes is that RapidAI's stroke module has been tested against a named competitor on consecutive unselected cases and held up, which no other vendor in this category can currently say. We go through what that study does and does not prove in the stroke AI buyer guide.

The second advantage is the neuro service line fit. Perfusion, midline shift quantification and longitudinal change tracking are the things a neurointerventional team asks for after the first year, and RapidAI ships them as cleared modules rather than research features. If your stroke program is the reason you are buying imaging AI at all, that depth is worth more than a wider indication list.

Where Aidoc is genuinely stronger

Breadth, and the operational economics that follow from it. Every additional imaging AI vendor costs a hospital an interface build, a security review, a BAA, a support escalation path and a line in the budget. A platform that covers hemorrhage, pulmonary embolism, aortic dissection, cervical spine fracture and incidental findings under one of each is cheaper to run than three specialists, even when each specialist scores marginally better in isolation.

The multi-condition clearance matters more than it sounds. Historically, running eight pathologies meant eight algorithms each making a separate pass at the same CT, with eight separate alert streams landing on the same radiologist. Clearing one device that triages 14 indications from a single pass changes the noise profile of the whole deployment, and alert fatigue is the failure mode that quietly kills imaging AI programs. Our page on AI triage in radiology covers what that reordering actually does to a worklist.

What FDA clearance does and does not settle here

Aidoc appears on the FDA AI-enabled medical device list with 33 authorization entries and RapidAI with 20, which puts both in the top ten of software-only radiology AI vendors. Neither number tells you much about clinical value. Counting entries rewards vendors that file many narrow submissions, and vendors themselves usually quote cleared findings or indications instead, which is a larger number counted a different way. The figure worth having is the K number for the specific module, modality and body region you plan to run, and the Indications for Use text that goes with it. We set out the verification steps and the four product codes behind radiology AI on the FDA approved AI medical device list for radiology.

One thing clearance never covers is what happens to your data and your network once a cloud triage platform is inside the perimeter. Both vendors will hand you a security package, and your team will need to map what is in it against the HIPAA safeguards and the SOC 2 controls you are already accountable for. Hospitals that run this well treat it as a repeatable control mapping exercise rather than a one-off PDF review, because the same questions come back with every subsequent vendor.

What does Aidoc or RapidAI cost?

Neither company publishes list pricing, and any figure you see quoted online is a secondhand account of one contract. What is public is the shape of the pricing: both are sold as annual subscriptions, usually scoped by site or by study volume and by which modules you enable. That means the number you negotiate depends heavily on how many modules you actually turn on, which is why per-module pricing and utilization reporting are worth insisting on before signature rather than after. We collected the broader picture of what imaging software costs in radiology software pricing.

Five questions that separate the two in a real evaluation

What is the alert path, and what watches it? Both products deliver value through a notification that reaches a human quickly. That path crosses your network, a vendor cloud and a push service. Ask what happens when a study fails to process, and whether that failure is visible to anyone.

How many modules will we actually use? Ask each vendor for utilization data from a comparable site. Aidoc's breadth argument only pays if the breadth gets used.

What is the false positive rate at our prevalence? Clearance data comes from the submission's dataset. Your emergency department's case mix is different, and false activations are what erode clinician trust in either platform.

Does it reorder the reading worklist, or only page someone? Triage and notification are separate behaviors, and some deployments deliver one without the other. Confirm which you are buying.

What does the exit look like? Interface teardown, data return and notice period. Ask before you need to know, and see radiology software contract negotiation for the terms worth fighting over.

How to choose between Aidoc and RapidAI

Two decision rules that hold up against the evidence available in 2026.

Buy RapidAI if stroke is the service line driving the purchase, if your neurointerventional team wants perfusion and quantification rather than a flag, and if published comparative performance on LVO detection is the number your clinical leadership will be judged on. Ask Aidoc to respond to the DUEL result directly, since they are entitled to point out it was not run against them.

Buy Aidoc if the purchase is being driven by emergency department throughput across many pathologies, if you are trying to avoid running three vendors, or if a single integration and a single security review is what makes the project approvable at all. Ask for utilization data from a site like yours, because breadth that goes unused is the failure mode here.

Whichever way you lean, negotiate a local validation window. Run the tool against your own consecutive cases, count the misses yourself, and keep an exit if measured local performance falls below a stated threshold. That is the only evidence that is actually about your patients. If you are still building the shortlist, our best AI radiology software roundup covers the wider category, and the individual Aidoc comparison and RapidAI comparison go deeper on each vendor on its own terms.